Caldera Therapeutics
Leading the march to IBD bispecifics
Boston, United States · Founded 2025 · $112.5M raised
- Headquarters
- Boston, Massachusetts
- Employees
- 1–10
- Founded
- 2025
- Business Model
- B2B
- Website
- calderatx.com
- Total Funding
- $112.5M
- Last Round
- $37.5M Series AJan 2026
- Rounds
- 2
About
Caldera Therapeutics is a clinical-stage biotechnology company founded in 2025 and headquartered in Massachusetts, developing CLD-423, a first-in-class bispecific antibody targeting the IL-23p19 and TL1A pathways for the treatment of inflammatory bowel disease (IBD) and other immunologic conditions. The company was built around a senior leadership team with deep IBD drug development experience, including CEO Praveen Tipirneni, formerly of Morphic Therapeutic. Caldera licensed CLD-423 from a Chinese partner and launched with $112.5 million in total funding from top biotech investors including Atlas Venture, LAV, venBio, Omega Funds, Wellington Management, and Janus Henderson. A Phase 1 healthy volunteer trial of CLD-423 is currently ongoing.
Summary
Caldera Therapeutics is a Biotech company based in Boston, United States, founded in 2025. It has raised $112.5M in total across 2 rounds, most recently a $37.5M Series A round in Jan 2026. Investors include Omega Funds, Atlas Venture and Wellington Management.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2026
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...